These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1161 related articles for article (PubMed ID: 30334521)

  • 1. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study.
    Abubakar I; Lalvani A; Southern J; Sitch A; Jackson C; Onyimadu O; Lipman M; Deeks JJ; Griffiths C; Bothamley G; Kon OM; Hayward A; Lord J; Drobniewski F
    Health Technol Assess; 2018 Oct; 22(56):1-96. PubMed ID: 30334521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation.
    Takwoingi Y; Whitworth H; Rees-Roberts M; Badhan A; Partlett C; Green N; Boakye A; Lambie H; Marongiu L; Jit M; White P; Deeks JJ; Kon OM; Lalvani A
    Health Technol Assess; 2019 May; 23(23):1-152. PubMed ID: 31138395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study.
    Abubakar I; Drobniewski F; Southern J; Sitch AJ; Jackson C; Lipman M; Deeks JJ; Griffiths C; Bothamley G; Lynn W; Burgess H; Mann B; Imran A; Sridhar S; Tsou CY; Nikolayevskyy V; Rees-Roberts M; Whitworth H; Kon OM; Haldar P; Kunst H; Anderson S; Hayward A; Watson JM; Milburn H; Lalvani A;
    Lancet Infect Dis; 2018 Oct; 18(10):1077-1087. PubMed ID: 30174209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.
    Pooran A; Booth H; Miller RF; Scott G; Badri M; Huggett JF; Rook G; Zumla A; Dheda K
    BMC Pulm Med; 2010 Feb; 10():7. PubMed ID: 20170555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.
    O'Shea MK; Fletcher TE; Beeching NJ; Dedicoat M; Spence D; McShane H; Cunningham AF; Wilson D
    PLoS One; 2014; 9(5):e97366. PubMed ID: 24816576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA.
    Nijhawan AE; Iroh PA; Brown LS; Winetsky D; Porsa E
    BMC Infect Dis; 2016 Oct; 16(1):564. PubMed ID: 27733123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative IFN-γ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study.
    Gupta RK; Lipman M; Jackson C; Sitch AJ; Southern J; Drobniewski F; Deeks JJ; Tsou CY; Griffiths C; Davidson J; Campbell C; Stirrup O; Noursadeghi M; Kunst H; Haldar P; Lalvani A; Abubakar I
    Am J Respir Crit Care Med; 2020 Apr; 201(8):984-991. PubMed ID: 31825645
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.
    Steffen RE; Caetano R; Pinto M; Chaves D; Ferrari R; Bastos M; de Abreu ST; Menzies D; Trajman A
    PLoS One; 2013; 8(4):e59546. PubMed ID: 23593145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.
    Auguste P; Tsertsvadze A; Pink J; Court R; McCarthy N; Sutcliffe P; Clarke A
    BMC Infect Dis; 2017 Mar; 17(1):200. PubMed ID: 28274215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.
    Doan TN; Eisen DP; Rose MT; Slack A; Stearnes G; McBryde ES
    PLoS One; 2017; 12(11):e0188631. PubMed ID: 29182688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country.
    Lin WC; Lin HH; Lee SS; Sy CL; Wu KS; Chen JK; Tsai HC; Chen YS
    J Microbiol Immunol Infect; 2016 Oct; 49(5):729-736. PubMed ID: 25442858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.
    Hamada Y; Gupta RK; Quartagno M; Izzard A; Acuna-Villaorduna C; Altet N; Diel R; Dominguez J; Floyd S; Gupta A; Huerga H; Jones-López EC; Kinikar A; Lange C; van Leth F; Liu Q; Lu W; Lu P; Rueda IL; Martinez L; Mbandi SK; Muñoz L; Padilla ES; Paradkar M; Scriba T; Sester M; Shanaube K; Sharma SK; Sloot R; Sotgiu G; Thiruvengadam K; Vashishtha R; Abubakar I; Rangaka MX
    EClinicalMedicine; 2023 Feb; 56():101815. PubMed ID: 36636295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia.
    Chkhartishvili N; Kempker RR; Dvali N; Abashidze L; Sharavdze L; Gabunia P; Blumberg HM; Del Rio C; Tsertsvadze T
    BMC Infect Dis; 2013 Nov; 13():513. PubMed ID: 24176032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease.
    Ayers T; Hill AN; Raykin J; Mohanty S; Belknap RW; Brostrom R; Khurana R; Lauzardo M; Miller TL; Narita M; Pettit AC; Pyan A; Salcedo KL; Polony A; Flood J;
    JAMA Netw Open; 2024 Apr; 7(4):e244769. PubMed ID: 38568690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of IGRA tests and TST in the diagnosis of latent tuberculosis infection and predicting tuberculosis in risk groups in Krakow, Poland.
    Kruczak K; Duplaga M; Sanak M; Cmiel A; Mastalerz L; Sladek K; Nizankowska-Mogilnicka E
    Scand J Infect Dis; 2014 Sep; 46(9):649-55. PubMed ID: 25073535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States.
    Dorman SE; Belknap R; Graviss EA; Reves R; Schluger N; Weinfurter P; Wang Y; Cronin W; Hirsch-Moverman Y; Teeter LD; Parker M; Garrett DO; Daley CL;
    Am J Respir Crit Care Med; 2014 Jan; 189(1):77-87. PubMed ID: 24299555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain.
    Calzada-Hernández J; Anton J; Martín de Carpi J; López-Montesinos B; Calvo I; Donat E; Núñez E; Blasco Alonso J; Mellado MJ; Baquero-Artigao F; Leis R; Vegas-Álvarez AM; Medrano San Ildefonso M; Pinedo-Gago MDC; Eizaguirre FJ; Tagarro A; Camacho-Lovillo M; Pérez-Gorricho B; Gavilán-Martín C; Guillén S; Sevilla-Pérez B; Peña-Quintana L; Mesa-Del-Castillo P; Fortuny C; Tebruegge M; Noguera-Julian A
    Eur J Pediatr; 2023 Jan; 182(1):307-317. PubMed ID: 36335186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.
    Vassilopoulos D; Tsikrika S; Hatzara C; Podia V; Kandili A; Stamoulis N; Hadziyannis E
    Clin Vaccine Immunol; 2011 Dec; 18(12):2102-8. PubMed ID: 21994356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.
    Kowada A; Takasaki J; Kobayashi N
    J Hosp Infect; 2015 Feb; 89(2):99-108. PubMed ID: 25559158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.